AbbVie (ABBV) Net Margin Growth (1y) (2013 - 2026)
AbbVie (ABBV) Net Margin Growth (1y) (2013 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Margin Growth (1y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
1,568.00 |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
-2,848.00 |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
-501.00 |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
29,782.00 |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
-5,859.00 |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
-12.00 |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
931.00 |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
- |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
- |
| 10 |
Biogen |
30.87 Bn |
26.59 Bn |
1.82 Bn |
300.00 |
| Date | Value |
|---|
| Mar 31, 2026 |
-501.00 |
| Dec 31, 2025 |
1,107.00 |
| Sep 30, 2025 |
-962.00 |
| Jun 30, 2025 |
-339.00 |
| Mar 31, 2025 |
-148.00 |
| Dec 31, 2024 |
-591.00 |
| Sep 30, 2024 |
-197.00 |
| Jun 30, 2024 |
-513.00 |
| Mar 31, 2024 |
1,194.00 |
| Dec 31, 2023 |
-1,059.00 |
| Sep 30, 2023 |
-1,389.00 |
| Jun 30, 2023 |
826.00 |
| Mar 31, 2023 |
-3,398.00 |
| Dec 31, 2022 |
-1,083.00 |
| Sep 30, 2022 |
451.00 |
| Jun 30, 2022 |
103.00 |
| Mar 31, 2022 |
604.00 |
| Dec 31, 2021 |
2,705.00 |
| Sep 30, 2021 |
439.00 |
| Jun 30, 2021 |
1,265.00 |
